Big names back US forest-backed carbon credit scheme
From Microsoft to a division of Royal Dutch Shell, big companies are buying carbon credits tied to more than 1mn acres of forested land in the US, venture-backed US climate company NCX said May 26.
NCX said it has created the largest forest carbon project by acreage in the Lower 48 states. Among the early participants are Microsoft, Shell’s environmental products division and sustainable consulting firm South Pole.
Zack Parisa, the founder of NCX, said the project puts carbon on the same footing as timber.
“NCX identifies forested acres that are likely to be harvested and rewards landowners that keep them growing,” he said. “It’s a solution that connects landowners with net-zero pioneers to create climate impact with unprecedented scale and transparency.”
Fintech firm Pipe secures $2bn valuation after funding round
Pipe allows companies to sell their recurring revenue streams
Pipe, a startup that allows companies to sell their recurring revenue streams, has secured a valuation of $2bn (£1.4bn) following a fresh funding round.
The fintech firm today said it had raised a further $250m in a round led by venture capital firm Greenspring Associates.
New investors such as Morgan Stanley’s investment arm Counterpoint Global, SBI Investment and Creditease Fintech Investment Fund also contributed to the funding.
Pipe, dubbed the “Nasdaq for revenue”, operates a trading platform that connects investors with companies seeking to raise capital without dilution.
Follow
Feb. 1, 2021
Bayer, one of the largest pharmaceutical companies in the world, has led a $40 million investment in an Israeli start-up developing solutions for allergies and food sensitivities using artificial intelligence and protein engineering.
The start-up, called Ukko, is focusing on two strategies. One is the growing of gluten without its allergenic components in plants such as wheat and corn, the other being the development of a medication that will “re-educate” the immune system so that it can overcome a peanut allergy. If the company succeeds in these ventures, this will have great significance for people with celiac disease or for people facing life-threatening peanut allergies.